LOXO ONCOLOGY, INC.
LOXO ONCOLOGY, INC. (LOXO): 8 pipeline candidates · ~29 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
29.3 months
D/E 0.74 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for LOXO ONCOLOGY, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$136.4M
Quarterly Burn
$61.4M
Runway
29.3 mo
Revenue
$42.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| bendamustine | Phase 3 |
| cabozantinib | Phase 3 |
| jaypirca | Approved |
| jaypirca | Approved |
| larotrectinib | BLA Filed |
| loxo-195 | Phase 2 |
| loxo-292 | Phase 1 |
| loxo-305 | Phase 3 |
Frequently asked questions
How many drug candidates are in LOXO ONCOLOGY, INC.'s pipeline?
LOXO ONCOLOGY, INC. (LOXO) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LOXO ONCOLOGY, INC.'s lead drug candidate?
LOXO ONCOLOGY, INC.'s most advanced tracked candidate is bendamustine (Phase 3) for Chronic Lymphocytic Leukemia.
What is LOXO ONCOLOGY, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LOXO ONCOLOGY, INC. has approximately 29.3 months of cash runway.
Who is the CEO of LOXO ONCOLOGY, INC.?
Joshua H. Bilenker, M.D. is the chief executive officer of LOXO ONCOLOGY, INC. (LOXO).
Get the full picture on LOXO ONCOLOGY, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.